and tonight's data is from hodgkin's lymphoma. this 96% complete response rate is also with less toxicity because we get rid of the worst drugs in the standard chemotherapy, so we see no lung toxicity and we see an improved complete remission rate. >> you already have something that's been approved so you don't have to worry about anything coming along that has a side effect that isn't quite evident now. is the fda going to look at this and say give us a couple more years of studies and maybe we'll use it, but right now we have something that works. >> that's exactly what happened. we have met with the fda and we have what's called a special protocol agreement, it's an spa. and this agreement is for the conduct of a pivotal phase three trial and we have one for hodgkin's lymphoma and an spa for t-cell lymphoma and the t-cell lymphoma trial should start within the next month or two and we're really excited to do those trials, get them done and then become the standard of care and really redefine front line therapy for all these pat

in front line hodgkin's lymphoma, it's about 10,000 patients a year just in the united states. if you look at the t-cell market, it's roughly 5,000 to 6,000 patients in the united states. so that market opportunity is substantial. >> you have currently said, you went through your most recent comps calls that jew oar going to have substantial sales next year, so i want to tell an investor in my show that absolutely wants to buy something, how do you balance flat next year with the possibility of a very exciting pine line for 2014, 2015? how do we view this? >> i think it's a good question, what you're asking. first of all, we didn't provide guidance yet for 2013 formally until february, which is our fourth quarter conference call, so then we'll be clear with what our guidance is for 2013. we look forward to a lot of catalysts coming up, we expect early next year approval in canada, we just recently got approval with our partner, approval in the 27 member countries and the european union. we are submitting early next year two supplemental or sblas with the fda, we expect a pletho

. >> reporter: three years ago, abby was diagnosed with hodgkin's' lymphoma a curable cancer of the immune system. >> it was harder on my parents. >> reporter: then 10, abby started chemotherapy and was doing well but then one of her drugs became unavailable due to a shortage. she was switched to another drug which was considered a safe and effective alternative. >>> we let them finish up her treatment with that but then at 12 weeks when we went back for the radiation she relapsed. >> reporter: now as reported in the new england journal of medical a closer look at the drug substitutionna . national clinical trial led by saint jude children's hospital the two-year cancer-free survival fell from 88% to 75% after the substitute drug was administered. >> this is the first studyclearly show that when we substitute one drug for another they are not all of us as good. >> reporter: because of the relapse she had to have a bone marrow transplant, radiation and more chemotherapy. now at 13 she is cancer-free. >> obviously it could have been worse. what if i relapsed another time. >> reporter: the pr

. >> reporter: abby alonzo was ten when diagnosed in 2009 with hodgkin's lymphoma, a cancer of the immune system. with proper treatment, 90% of patients survive. >> it wasn't as hard for me as i think it was on my mom, my brother, my dad. >> reporter: abby began a seven- drug regimen, but, in 2010, doctors told abby's mother, katie, there was a nationwide shortage of one of the medicines, mechlorethamine. >> i start to get a little hysterical. why is it not available? >> reporter: that year, 23 cancer drugs had shortages. reasons included manufacturing problems and low-profit margins for the drug, which became mostly generic and less expensive than brand names. there really is nothing you can do. you do what your doctor tells you to do. you take what medications your doctor tells you to take, and you pray that it works. and if one of those medications isn't available, you just take, you know, the next best thing. >> reporter: doctors thought the "next best thing" for patients like abby was a drug called cyclophosphamide. but the new study showed 88% treated with the original drug were can

in 2010, a hodgkin's lymphoma out medication was in low supply day prescribed a substitute. researchers at st. jude looked at hundreds of medical records and they found one in four given the new treatment had a relapse compared to one in eight that were given the original. none died, but those who relapsed did need more toxic drugs to recover. the secret to treating millions of cancer patients might be hidden in a mushroom. it is called the turkey tail, commonly found in northwestern forests. physicians have been using it for centuries to boost the body's immune systems and researchers at a natural healing university got permission from the fda to study their qualities. one cancer patient, lisa clinton, said she turned to the measures to boost her immune system. >> one son was diagnosed, i shut everything down. >> when ingested, they stimulate immune cells that line the intestines. they stimulate other immune cells all over the body. >> clinton says so far it is boosting her immune system and boosting her outlook on life. >> now your 11 insta-weather + forecast with meteorol

known, 20 years later in august 1988, my wife and i lost our first-born son, elmo iii, from both hodgkins disease and nonhodge consistent lymphoma. i have been deeply saddened by the additional insights i have gained. chemical companies have known for many years that these substances were harmful. they had exchanged data amongst themselves about such harmful effects and have delayed in some cases many years in making reports to government concerning these harmful effects. bud zumwalt -- close the quote. bud zumwalt had asked all the right questions, but he received dishonest answers. and he was intent on never letting that happen again. so at the time of the persian gulf war, bud's thoughts were on the fact that it took the government 15 years to deal with agent orange. adding to this was he and his wife's anxiety and the fact that their surviving son jim, who's here in the front row, was deployed in the gulf. and as soon as president bush began the deployments, bud called secretary of defense cap weinberger to urge that daily positions be taken of all tactical units, be recorded so that